A packing material, wherein to a porous organic polymer carrier including 60 to 95 mol % of a repeating unit derived from glycidyl methacrylate and 5 to 40 mol % of a repeating unit derived from a polyfunctional monomer, one end of at least one alkylene group selected from a linear alkylene group, a cycloalkylene group, and a linear alkylcycloalkylene group, having 4 to 9 carbon atoms is bonded by a glycidyl group derived from glycidyl methacrylate, and an other end of the alkylene group is bonded to any one end of a polyol via an ether bond.

The invention provides ubiquitin variants that specifically bind to HECT E3 ligases, and methods of using these variants to modulate the activity of HECT E3 ligases.

Provided herein are methods of treatment designed to prevent or minimize formation of deleterious multivalent immune complexes in a human patient having a complement mediated disorder (e.g., paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS)), who has been or is being treated with a first anti-C5 antibody and is then treated with a second (different) anti-C5 antibody, as well as methods of safely switching a patient from treatment with a first anti-C5 antibody to a second (different) anti-C5 antibody. Also provided are methods for determining an adjusted regimen antibody (e.g., a regimen to prevent or minimize formation of multivalent immune complexes) comprising an adjusted therapeutic dose and/or timing of administration of a second anti-C5 to treat a patient who has been or is being treated with a first anti-C5 antibody.

The present invention is directed to a method for performing size exclusion chromatography. Embodiments of the present invention feature devices and methods for improving the speed and separations of size exclusion chromatography using a stationary phase material comprising small particles (<2 micron in diameter).

This application pertains to methods of isolating virus particles and producing virus vaccine composition comprising subject a biological sample to an anion exchange chromatography and a hydroxyapatite chromatography. The application also pertains to rabies virus vaccine compositions and methods of assessing suitability of a virus vaccine composition or releasing a commercial batch of virus vaccine composition for clinical use.

A chromatograph mass spectrometer including: an MS.sup.n-1 analysis setter for setting an analysis execution period for performing an MS.sup.n-1 analysis, an execution time for the analysis and a loop time; an analysis period divider for dividing the analysis period into segments according to a change in number or analysis condition of MS.sup.n-1 analyses to be performed within the same time window; an MS.sup.n analysis setter for performing MS.sup.n-1 analysis to obtain mass spectrum data and for scheduling MS.sup.n analysis, an ion corresponding to a peak satisfying a set condition being designated as a precursor ion; an MS.sup.n analysis execution time allotter for allotting, in each segment, a time period for execution of the MS.sup.n analysis, the time period being calculated by subtracting an event execution time from the loop time; and an analysis executer for repeatedly performing MS.sup.n-1 analysis and MS.sup.n analysis in each segment.

This application pertains to methods of isolating virus particles and producing virus vaccine composition comprising subject a biological sample to an anion exchange chromatography and a hydroxyapatite chromatography. The application also pertains to rabies virus vaccine compositions and methods of assessing suitability of a virus vaccine composition or releasing a commercial batch of virus vaccine composition for clinical use.

This application pertains to methods of isolating virus particles and producing virus vaccine composition comprising subject a biological sample to an anion exchange chromatography and a hydroxyapatite chromatography. The application also pertains to rabies virus vaccine compositions and methods of assessing suitability of a virus vaccine composition or releasing a commercial batch of virus vaccine composition for clinical use.

This application pertains to methods of isolating virus particles and producing virus vaccine composition comprising subject a biological sample to an anion exchange chromatography and a hydroxyapatite chromatography. The application also pertains to rabies virus vaccine compositions and methods of assessing suitability of a virus vaccine composition or releasing a commercial batch of virus vaccine composition for clinical use.

Provided is a method for quantifying a specific component contained in a measurement sample. The method includes: obtaining a measurement spectrum at each of a plurality of points in time by analyzing the measurement sample with chromatography; deriving an index value at each point of the plurality of points in time, by applying a filter for extracting the specific component, to the measurement spectrum at the point of the plurality of points in time; obtaining a chromatogram by arranging one or more index values at respective one or ones of the plurality of points in time; and quantifying the specific component based on a peak of the chromatogram.